The Investigation for New Discovery of Biomarkers
BioFIND is an observational clinical study designed to discover and verify biomarkers of Parkinson's disease (PD).†The study was carried out at eight academic sites in the United States. Recruitment began in 2012 and closed in March of 2015. BioFIND collected clinical data and biospecimens, including blood and cerebrospinal fluid (CSF), in well-defined, moderately advanced PD subjects and healthy controls.
BioFIND followed standardized data acquisition protocols to ensure that tests and assessments conducted at multiple sites could be pooled. Data and samples acquired from study participants have been placed in a comprehensive Parkinson's database and biorepository and are available to the scientific community for research on novel PD biomarkers. The study aims to complement PPMI to produce the most comprehensive and long-ranging dataset available for biomarker discovery work throughout the PD community. †
Only with collaborative efforts like BioFIND can we efficiently discover and verify biomarker candidates for PD. This study is sponsored by The Michael J. Fox Foundation for Parkinson's Research with support from the National Institute of Neurological Disorders and Stroke (NINDS).
Accessing Clinical Data and Biospecimens
Clinical data and biospecimens from BioFIND are available for request. Clinical data from BioFIND is hosted by the study Bioanalytics Core†and applications for data access are reviewed in real time. More information about using the BioFIND data can be found on Accessing BioFIND Data. To request access to available BioFIND samples, please complete and submit an application to the centralized X01-Request to access Parkinsonís disease related-biospecmens program. Questions about the application process for BioFIND samples can be directed to email@example.com.
Biospecimens from BioFIND are available to qualified researchers and requests are reviewed by a Biospecimen Resource Access Committee (BRAC). A detailed review of the process can be found on Accessing Data and Biospecimens program. The following research studies have been approved for sample use.†
|Project Title||Principial Investigator||Institution||Specimen Used|
|CRP40 Expression as a Biomarker of Parkinson's Disease||Ram Mishra, PhD||CRP40 Inc.||RNA|
|Verification of a long-noncoding RNA in blood as a biomarker for Parkinson's disease||Antony Cooper, PhD||Garvan Institute of Medical Research||RNA|
|Analysis of circulating brain-enriched microRNAs as biomarkers for Parkinson's disease||Samuil Umansky, MD, PhD||DiamiR, LLC||Plasma|
|Metabolomic analysis of Parkinsonian disorders||Peter LeWitt, MD||Henry Ford Hospital||
CSF and Plasma
|Comprehensive analysis of brain and peripheral biogenic small molecule levels in Parkinson's Disease||Omar Mabrouk, PhD||University of Michigan||
|Lysosomal enzymes activity and GBA1 genotyping in CSF of Parkinson's Disease patients: A Confirmatory Study||Lucilla Parnetti, MD, PhD||University of Perugia||
DNA and Plasma
|Parkinson's Disease Biomarker Search in Cerebrospinal Fluid by Ambient Ionization Mass Spectrometry||Robert G. Cooks, PhD||Purdue University||
Available Biospecimens and Data*
|Clinical Data||Whole Blood Pellet||Plasma||Saliva||Urine||DNA||RNA||CSF|
*Numbers refer to submission from unique individuals. Typical submissions include: clinical data, 2 whole blood pellets, 12 ml plasma from whole blood, 8.5 ml whole blood for DNA extraction, 5-10 ml whole blood for RNA extraction, 10 ml cerebrospinal fluid.